



CLX Medical, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563
Telephone: (951) 677-6735 / Facsimile: (951) 677-6573
investors@clxinvestments.com
www.clxinvestments.com

June 2008 Newsletter

CLX Medical, Inc. Announces Status of Validation Study for Zonda's Rapid Point of Care Test for Chlamydia

Inside This Issue

Greeting from CEO Vera Leonard
Page 2

Status of Proposed Acquisition of Additional Medical Diagnostic Testing Product is Updated
Page 2

About the Company

CLX Medical, Inc. is focused on the launch and distribution of unique medical diagnostic testing products. CLX holds a 51% equity interest in Zonda, Inc. and holds a common stock position, in ActionView International, Inc., a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

For more information, please visit the CLX website at www.clxinvestments.com and the Zonda website at www.zondaincusa.com.

To sign up to receive information from the company by email, please visit www.clxinvestments.com/email.php.

C LX Investment Company, Inc., which is focused on the launch and distribution of unique medical diagnostic testing products, has provided an update on the pre-clinical trials validation study for Zonda Incorporated's rapid point of care test for chlamydia.

A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.

CLX has been informed that the study will take longer to complete than originally planned. We do not have a revised estimate of completion at the moment but expect that it will be within a few weeks or, at best, several days.

Vera Leonard, chief executive officer of Zonda and CLX, commented, "While we expected to have results of the in vitro validation study ready to report to shareholders and the public markets by mid-June, adequate growth of chlamydia cells has not yet been achieved. Unpredictability is unfortunately an inherent element of any clinical study process, so this delay does not come as a complete surprise. Living organisms utilized in a clinical study are, by their very nature, somewhat unpredictable. Quite simply, the bacteria do not always cooperate.

"Our original estimate of the amount of time required to complete the validation study included the time to acquire chlamydia samples, and the issue with the samples has obviously delayed the completion of the study. The laboratory is working hard to acquire appropriate samples so we can complete the study as soon as possible. We are committed to keeping our shareholders informed and will provide updates including specific timelines whenever possible," Ms. Leonard added.

CLX currently holds a majority interest in Zonda, whose tests utilize proprietary technology that detects enzymes that are specific to the target

(continued on page 2)



Zonda Incorporated

CLX Medical Provides Update on Status of Proposed Acquisition of Medical Diagnostic Testing Product

CEO reports to shareholders that continued due diligence is expected to lead to definitive agreement for acquisition

CLX Investment Company, Inc. issued an update on the anticipated acquisition of an additional rapid diagnostic device for the medical market.

CLX Medical announced that it had entered into a letter of intent to acquire the product on April 30, 2008 and stated that the due diligence process would continue as the company pursued a definitive agreement and the close of the acquisition of the device. The announcement also stated that once CLX had reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.

"We continue in the due diligence process regarding this product, and we do expect that this process will result in a definitive agreement for the acquisition," commented Vera Leonard, chief executive officer of Zonda and CLX Medical. "We take the due diligence period very seriously and believe that for the protection of CLX shareholders and the benefit of both parties involved, there should not be a rush to close a transaction until all of the appropriate preliminary work has been completed."

"We remain committed to keeping our shareholders informed as this process moves forward, and will provide updates whenever possible," she added.

The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia.

CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. A validation study is underway to perfect the testing protocol in preparation for the clinical trials.

Greetings from the CEO

This month's CLX Medical corporate newsletter updates two very important aspects of the company's current operations: the status of the ongoing pre-clinical trials validation study for Zonda's rapid point of care test for chlamydia and an update on the anticipated acquisition of an additional rapid diagnostic device for the medical market.



As you are now aware, the study will take longer to complete than originally planned due to the fact that adequate growth of chlamydia cells has not yet been achieved. We are fully committed to the completion of the study; however, the process cannot be rushed.

We are also still engaged in the due diligence process for the new targeted acquisition. This is an extremely important undertaking, especially as it provides protection for the company and its shareholders. In addition to the usual legal, financial and compliance due diligence, we have initiated some strategic planning for post-acquisition distribution of the product into worldwide markets. We would likely not be undertaking this work unless we believed very strongly that a definitive agreement and the close of the acquisition of the device will ultimately be achieved.

The coming weeks and months are shaping up to be a potentially exciting time for CLX Medical, and we look forward to reporting additional progress in each of these areas as soon as possible.

Best regards,
Vera Leonard, Chief Executive Officer

Status of Validation Study for Zonda's Chlamydia Test is Updated

(continued from page 1)

microorganisms and are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets. Zonda's chlamydia product has been distributed in Europe for approximately three years.

According to the Centers for Disease Control and Prevention, Chlamydia trachomatis infections are the most commonly reported notifiable disease in the U.S. They are among the most prevalent of all STDs and, since 1994, have comprised the largest proportion of all STDs reported to CDC.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.